American Journal of Kidney Diseases
Volume 50, Issue 5 , Pages 700-702 , November 2007

On Statin Treatment to Prevent Sepsis in Dialysis Patients

  • Christoph Wanner, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Christoph Wanner, MD, University of Würzburg, Division of Nephrology, University Hospital Würzburg, Josef Schneider Strasse 2, Würzburg, Germany 97080.

References 

  1. Foley RN, Guo H, Snyder JJ, Gilbertson DT, Collins A. Septicemia in the United States dialysis population, 1991-1999. J Am Soc Nephrol. 2004;15:1038–1045
  2. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138–150
  3. Ishani A, Collins AJ, Herzog CA, Foley RN. Septicemia, access and cardiovascular disease in dialysis patients (The USRDS Wave 2 study). Kidney Int. 2005;68:311–318
  4. Gupta R, Plantinga LC, Fink NE, et al. Statin use and hospitalization for sepsis in patients with chronic kidney disease. JAMA. 2007;297:1455–1464
  5. Ollendorf DA, Fendrick AM, Massey K, Williams GR, Oster G. Is sepsis accurately coded on hospital bills?. Value Health. 2002;5:79–81
  6. Merx MW, Liehn EA, Janssen U, et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation. 2004;109;:2560–2565
  7. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006;367:413–418
  8. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New Engl J Med. 2005;353:238–248
  9. Goldfarb-Rumyantzev AS, Habib AN, Baird BC, Barenbaum LL, Cheung AK. The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis. Am J Kidney Dis. 2007;50:791–802
  10. Levy MM, Fink MP, Marshall JC, et al. CCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003;29:530–538
  11. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002;110:285–288
  12. Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: a large case-control study of US Veterans. Chest. 2007;131:1282–1288
  13. Strazzullo P, Kerry SM, Barbato A, Versiero M, D’Elia L, Cappuccio FP. Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. Hypertension. 2007;49:792–798
  14. Gulcan E, Gulcan A, Erbilen E, Toker S: Statins may be useful in diabetic foot ulceration treatment and prevention. Med Hypotheses (in press)
  15. Davignon J, Leiter LA. Ongoing clinical trials of the pleiotropic effects of statins. Vasc Health Risk Manag. 2005;1:29–40

PII: S0272-6386(07)01251-6

doi: 10.1053/j.ajkd.2007.09.009

American Journal of Kidney Diseases
Volume 50, Issue 5 , Pages 700-702 , November 2007

Article Tools

* Image Usage & Resolution